Psychobiotics put the gut-brain axis on vets’ radar: full analysis
The gut-brain axis is getting fresh attention in companion animal medicine after dvm360 published an April 29, 2026, interview with Callie Harris, DVM, from Fetch Charlotte focused on psychobiotics, or probiotics intended to support mental health through microbiome signaling. Harris described a bidirectional pathway between the gut and brain and said emerging research suggests some probiotic interventions may reduce stress-related biomarkers such as cortisol while increasing serotonin-related signaling. (dvm360.com)
The idea itself isn't new. Harris noted the term psychobiotic dates back to 2013, and the veterinary nutrition field has been building around the concept for several years. Reviews in dogs and cats have increasingly linked the microbiome to behavior, cognition, and stress physiology, while also emphasizing how much remains unresolved about mechanism, reproducibility, and clinical relevance. A 2021 review on nutritional management of behavior and brain disorders in dogs and cats described the evidence for gut involvement in behavior as growing, and a 2024-2025 wave of reviews has pushed further into anxiety, dysbiosis, and microbiome-targeted interventions. (dvm360.com)
What changed here is less a regulatory or treatment milestone than a visibility shift: psychobiotics are moving from niche research language into mainstream veterinary media and CE programming. In the dvm360 interview, Harris, who is a Purina veterinarian, pointed to data from probiotics in the Purina portfolio showing decreased cortisol and increased serotonin-related effects in pets with anxiety. Purina Institute materials add more detail, describing a blinded crossover study in anxious dogs supplemented with Bifidobacterium longum in which many dogs had lower salivary cortisol and heart rate, and appeared less reactive during anxiety-provoking stimuli. (dvm360.com)
Still, the wider evidence base is more cautious than the headline concept may suggest. Systematic and narrative reviews in veterinary medicine say the gut-brain axis is biologically plausible and clinically promising, but they also note that studies are few, often small, and highly strain-specific. Recent literature has highlighted select strains such as Bifidobacterium longum and Lactiplantibacillus plantarum as potentially relevant to canine anxiety or behavior, yet reviewers repeatedly conclude that larger, better-controlled trials are needed before microbiome-based behavioral interventions can be considered broadly established. (pmc.ncbi.nlm.nih.gov)
Industry and expert commentary is also trending toward a multimodal view rather than a single-product solution. Purina Institute educational materials and event programming frame the gut-brain axis as one component of behavioral care, alongside environmental management, medication when indicated, and broader nutritional support. Cornell's veterinary guidance for pet parents similarly notes that probiotics may have applications beyond GI health, including anxiety, but advises caution, especially in severely immunocompromised dogs and in situations where evidence is still developing. (purinainstitute.com)
Why it matters: For practicing veterinarians, this is a reminder that behavioral medicine and GI medicine are increasingly intersecting. Dogs presenting with anxiety, noise aversion, separation-related distress, or chronic stress may also have GI disruption, and the reverse may be true as well. That doesn't mean every anxious patient needs a probiotic, or that any probiotic will do. It means clinicians may want to think more deliberately about strain-specific evidence, product quality, concurrent GI signs, and how to explain to pet parents that microbiome support is best viewed as an adjunct, not a replacement, for evidence-based behavior treatment. (purinainstitute.com)
The commercial angle also matters. Much of the most visible canine psychobiotic data is tied to industry-backed research and education, particularly from Purina Institute. That doesn't invalidate the findings, but it does make independent replication important before the category becomes routine in general practice. Earlier veterinary reviews have also raised quality and labeling concerns across the broader probiotic market, reinforcing the need for careful product selection rather than assuming class-wide benefit. (dvm360.com)
What to watch: The next meaningful development will be more independent, peer-reviewed clinical trials in dogs and cats, ideally with standardized behavioral endpoints, clearer strain identification, and longer follow-up. Until then, expect psychobiotics to remain a promising but still maturing tool in the larger conversation about nutrition, behavior, and whole-patient care. (pmc.ncbi.nlm.nih.gov)